Related Experiment Video

Updated: Aug 16, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

CDK4/6 inhibitor resistance: A bibliometric analysis

Jiayuecheng Pang1, Hengyu Li1, Yuan Sheng1

  • 1Department of Breast and Thyroid Surgery, Changhai Hospital, Naval Military Medical University, Shanghai, China.

Frontiers in Oncology
|December 19, 2022
PubMed
Abstract

Insights

This bibliometric analysis maps the research landscape of cyclin-dependent kinases (CDK) 4/6 inhibitor resistance. It identifies key trends and authors, offering insights into drug resistance mechanisms and future research directions for CDK4/6 inhibitors.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Cyclin-dependent kinases (CDK) 4/6 inhibitors block cell proliferation by inhibiting retinoblastoma protein (Rb) phosphorylation.
  • These inhibitors are primarily used for hormone receptor-positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer, often with endocrine therapy.
  • Drug resistance remains a significant challenge, limiting the efficacy of CDK4/6 inhibitors.

Purpose of the Study:

  • To summarize and visualize the current research landscape and development trends in CDK4/6 inhibitor resistance.
  • To provide clinicians and researchers with a comprehensive overview of past research and future directions.
  • To identify emerging research areas and potential knowledge gaps in the field of CDK4/6 inhibitor resistance.

Main Methods:

  • Bibliometric analysis of articles from Web of Science Core Collection and PubMed (1996-2022).
  • Utilized R language, Bibliometrix, Vosviewer, GraphPad Prism, and Microsoft Excel for statistical analysis and visualization.
  • Included 1278 articles from Web of Science and 1123 from PubMed, analyzing publication trends, influential journals, authors, and research focus.

Main Results:

  • The field shows a significant annual growth rate (14.56% in Web of Science, 17.41% in PubMed).
  • Cancer Research is a leading journal, and key researchers include Malorni Luca and Turner Nicholas C.
  • Current research focuses on Palbociclib and Abemaciclib, with investigations into resistance mechanisms involving MEK, PI3K-AKT-MTOR, EGFR, and MAPK pathways.

Conclusions:

  • This bibliometric study offers a reliable foundation for understanding research trends in CDK4/6 inhibitor resistance.
  • It guides researchers in identifying authoritative references and exploring under-researched areas.
  • The findings provide valuable insights for future research and clinical strategies to overcome drug resistance.
Keywords:
CDK4/6 inhibitorbibliometricsbreast cancerresearch frontierresistance

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.7K